FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
View / Open Files
Authors
Wong, Kah Keng
Gascoyne, Duncan M
Soilleux, Elizabeth J
Lyne, Linden
Spearman, Hayley
Roncador, Giovanna
Pedersen, Lars M
Møller, Michael B
Green, Tina M
Banham, Alison H
Publication Date
2016-08-16Journal Title
Oncotarget
ISSN
1949-2553
Publisher
Impact Journals, LLC
Volume
7
Issue
33
Pages
52940-52956
Language
eng
Type
Article
This Version
VoR
Physical Medium
Print
Metadata
Show full item recordCitation
Wong, K. K., Gascoyne, D. M., Soilleux, E. J., Lyne, L., Spearman, H., Roncador, G., Pedersen, L. M., et al. (2016). FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.. Oncotarget, 7 (33), 52940-52956. https://doi.org/10.18632/oncotarget.9507
Abstract
FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy (R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with significantly inferior overall survival (OS: P = 0.0017) and progression-free survival (PFS: P = 0.0096). This remained significant in multivariate analysis against either the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression. Specifically in ABC-DLBCL these were associated with lower expression of immune response and T-cell receptor signaling pathways. Further studies are warranted to investigate the potential functional cooperativity between FOXP1 and FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL.
Keywords
FOXP2, diffuse large B-cell lymphoma, survival, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Cyclophosphamide, Doxorubicin, Female, Forkhead Transcription Factors, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Gene Ontology, Humans, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Prednisone, Protein Binding, Repressor Proteins, Signal Transduction, Transcriptome, Vincristine, Young Adult
Identifiers
External DOI: https://doi.org/10.18632/oncotarget.9507
This record's URL: https://www.repository.cam.ac.uk/handle/1810/287122
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk